- 1 **Title:** Caesarean myomectomy is not a risk factor for blood products transfusion among pregnant
- 2 individuals with fibroids: a retrospective cohort study.
- 3 **Authors:** Jarvi S<sup>1</sup>, Aviram A<sup>1</sup>, Joliffe C<sup>1</sup>, Wortsman S<sup>1</sup>, Liu GY<sup>1</sup>, Berndl A<sup>1</sup>, Barrett J<sup>1</sup>, Kroft J<sup>1</sup>
- <sup>4</sup> <sup>1</sup>Department of Obstetrics and Gynaecology, Sunnybrook Health Sciences Centre, University of
- 5 Toronto, Canada
- 6
- 7 **Disclosures:** The authors report no conflict of interest. JK was on the speakers bureaus and
- 8 receives consulting fees from Abbvie corporation and Pfizer, consulting fees from Ethicon and
- 9 Organon
- 10 **Funding:** No sources of funding
- 11 **Presentation:** No presentations
- 12 **Disclaimer:** None
- 13 **Corresponding Author:** Stephanie Jarvi. Address: Sunnybrook Health Sciences Centre 2075
- 14 Bayview Avenue, North York, ON M4N 3M5.
- 15 Acknowledgements: None
- 16

#### 2

### 17 ABSTRACT

18 Background: Uterine fibroids are common benign tumors during reproductive age. Among pregnant individuals with uterine fibroids, myomectomy at the time of cesarean delivery (CD) 19 20 allows individuals to avoid a second surgery later in life. 21 Objective: To examine the safety of myomectomy performed at the time of CD and the factors 22 that increase the risk of greater blood loss in cesarean myomectomy. 23 Study design: This was a retrospective cohort study of all cesarean myomectomies (CM) 24 performed at a tertiary care center in Toronto, Ontario between January 1, 2012, and June 1, 2019. The study group included individuals who had CM, and the control group included 25 26 individuals with fibroids who had a CD without removing their fibroids. The primary outcome 27 was the rate of blood products transfusion. Secondary outcomes were the need for hysterectomy and estimated blood loss (EBL). Subgroup analyses were performed for fibroid size, previous 28 29 CD, and elective vs urgent CD. Logistic regression analysis was performed to assess for 30 confounders. 31 Results: Overall, 110 CM were compared with 152 CD. The overall transfusion rate for CM was 32 7.3% compared to 0.7% in the control group (p = 0.005). All procedures requiring transfusion from both groups were performed  $< 37^{0/7}$  weeks of gestation. In logistic regression analysis, 33 34 performing a myomectomy was not associated with a higher risk for transfusion. The only 35 factors associated with transfusion were preterm birth (aOR 14.43, p=0.049) and low pre-36 operative hemoglobin (aOR 0.90, p=0.02). The median reported EBL was 800 mL for CM and

37 700 mL for controls (p<0.001). No individuals in either group required concomitant

hysterectomy. Subgroup analysis showed that fibroid size  $\geq$ 5cm and previous CD were not

- 39 associated with increased risk of transfusion among those who had a CM, while urgent CM was
- 40 significantly associated with the need for transfusion (p=0.02).
- 41 Conclusion: This study demonstrates that the transfusion rate was not significantly higher in
- 42 those undergoing CM at term, compared to those with fibroids undergoing CD without a
- 43 myomectomy.

#### 4

### 44 INTRODUCTION

45 Uterine fibroids are common benign tumors, that originate from the smooth muscle layer of the uterus<sup>1</sup>. It is estimated that fibroids occur in over 70% of biologically female individuals by the 46 onset of menopause<sup>2</sup>. Individuals with fibroids are often asymptomatic, however, symptoms may 47 include uterine bleeding, pelvic pain, pressure, and infertility<sup>3</sup>. There are multiple treatment 48 options including medical, surgical, or image-guided. Myomectomy and hysterectomy are the 49 mainstays of surgical treatment. While hysterectomy is a definitive treatment, myomectomy is 50 51 reserved for those individuals wishing to preserve fertility. 52 Fibroids are also common among pregnant individuals and are becoming more frequent as maternal age increases. While they are often asymptomatic, they may cause pain, pressure, or 53 54 preterm labor. If left untreated, many of these individuals will require surgical treatment later in life, and it is estimated that treatment will be required in 25% of individuals with fibroids<sup>2</sup>. 55 Cesarean delivery (CD) presents a unique opportunity to simultaneously perform a myomectomy 56 57 with the CD, possibly preventing a second surgery in the future. Cesarean myomectomy (CM), 58 however, is controversial. It has historically been discouraged because of the risk of excessive 59 hemorrhage causing anemia or requiring blood products transfusion, the risk of unnecessary hysterectomy, puerperal infection, and increased operative time<sup>4</sup>. However, more recent 60 61 literature has supported CM to be a safe procedure with only a small increase in operative time and no increased risk of post-operative complications<sup>5,6</sup>. Furthermore, there may be benefits of 62 63 doing a CM, such as a smaller uterine incision because the uterus/fibroid ratio is increased and the fibroid cleavage plans are easier to find<sup>7</sup>. As well, the natural uterine contractibility and 64 involution of the postpartum period reduces hemorrhage<sup>8</sup>. 65

- 66 Although recent systematic reviews and meta-analyses of observational studies have provided
- 67 favorable evidence to support carrying out CM, the data is heterogeneous in terms of the control
- 68 groups and types of fibroids removed and there is potential bias from the included studies.
- 69 The purpose of this study was to therefore compare the surgical outcomes of individuals
- 70 undergoing CM compared to those with fibroids undergoing CD alone.

We conducted a single-center retrospective cohort study of all CM performed between January 1,

6

### 71 METHODS

72

73 2012, and June 1, 2019. A control group of individuals that underwent CD in which fibroids 74 were identified but not removed was evaluated over a similar period. These individuals were 75 identified from the hospital database and data was extracted from patient records. Extracted data included demographics such as maternal age (years), parity, gestational age at 76 77 delivery (determined by first trimester ultrasound), previous myomectomy, and size and number of fibroids removed. The primary outcome was the rate of blood products transfusion. Secondary 78 79 outcomes were the need for hysterectomy, length of surgery (minutes) and estimated blood loss 80 (EBL, mL, determined subjectively by the surgical team), and change in hemoglobin (Hb) from 81 pre-operative (within one month of surgery) to post-operative (day 1 after surgery). Individuals 82 with a history of a documented bleeding disorder, multiple gestation, pre-eclampsia, 83 chorioamnionitis, placenta previa, placenta accrete spectrum disorders, or abruption were 84 excluded. Subgroup analyses were performed comparing outcomes for individuals depending on 85 fibroid size ( $\geq$  or < 5cm), previous CD, and elective vs urgent CD. 86 Statistical analysis was performed using SPSS version 28.0 (IBM, Armonk, NY, USA). 87 Continuous variables were analyzed using the Mann-Whitney U test, and categorical variables 88 using the chi-square or Fisher's exact test, as needed. A logistics regression analysis was 89 performed to account for potential confounders, and a sub-group analysis was performed as well 90 among the individuals who had a myomectomy. The significance level was determined at p < p0.05. This study was approved by the hospital Research Ethics Board (Project Identification 91 Number: 212-2019). 92

#### 7

#### 93 **RESULTS**

94 Overall, 262 individuals met the inclusion criteria and were included in the study: 110 (42%) who underwent a myomectomy during their cesarean delivery (CM group), and 152 (58%) who 95 96 had fibroids that were not removed during their CD (CD group). The participants in the CM group were characterized by a higher rate of previous surgery for 97 98 myomectomy, slightly lower gestational age at the time of delivery, and a higher rate of elective 99 procedure. No other demographic characteristics were found to be different between the groups (Table 1). 100 101 As for the procedures, CM took approximately 13.5 minutes longer to complete compared with 102 regular CD (47.0 vs 60.5 minutes, p<0.001). The estimated blood loss was higher in the CM 103 group, as was the rate of post-procedure need for blood products transfusion (Table 1). Yet, the 104 difference between the hemoglobin level before and after the procedure was not significantly 105 different between the groups (21 mg/dL in the CM group vs. 20 mg/dL in the CD group, 106 p=0.25). 107 To account for potential confounders for the need for post-procedure transfusion, a logistic

108 regression model was calculated using the following factors: Myomectomy, pre-operative

109 hemoglobin level, preterm birth, maternal age, previous surgery for myomectomy, previous CD

and urgent vs. non-urgent procedure (Table 2). Pre-operative hemoglobin level and preterm birth

111 were found the be independent risk factors for transfusion, but myomectomy during the CD was

112 not (aOR 5.4. 95% CI 0.47-61.6, p=0.18).

113 Size of fibroid:

114	Out of the 110 individuals who had a myomectomy, 53 (48%) had a fibroid size less than 5 cm
115	(<5cm), and 57 (52%) had a fibroid size greater or equal to 5 cm ( $\geq$ 5cm). Those with larger
116	fibroid size were characterized by a lower rate of previous surgery for myomectomy, their CM
117	took approximately 8 minutes longer, and their estimated blood loss was higher, compared with
118	the smaller fibroid group. However, the hemoglobin difference before and after the procedure,
119	and the rate of postpartum transfusion were not significantly different between the groups (Table
120	3a).
121	Previous cesarean section (CS):
122	Overall, of the individuals with CM, 81 individuals (74%) had no previous CD and 29 (26%) had
123	at least one previous CD. There was no significant difference in the hemoglobin decline from
124	before to after the procedure, or in the rate of postpartum transfusion between the groups (Table
125	3b).
126	Urgent versus elective procedure:
127	Of the individuals with CM, 41 (37%) participants had an urgent procedure and 69 (63%) had an
128	elective procedure. The urgent CM group was characterized by a higher rate of primiparity and a
129	lower gestational age at delivery (Table 3c). The procedure duration was not significantly
130	different between the two groups. The pre-operative hemoglobin and hemoglobin differences
131	from before to after surgery were also not significantly different between the two groups.
132	However, the estimated blood loss was higher by approximately 100mL in individuals with
133	urgent CM, the post-operative hemoglobin was lower by approximately 10mg/dL, and the rate of
134	post-procedure blood transfusion was higher among individuals with urgent CM (14.6% in
135	urgent CM group vs 2.9% in elective CM group, p=0.02) (Table 3c).

9

136

#### 137 DISCUSSION

138 In this cohort of pregnant individuals with fibroids undergoing cesarean delivery, 42% had a concurrent myomectomy at the time of delivery. Participants who underwent CM had a slightly 139 140 longer procedure duration than their counterparts who did not have a myomectomy during the 141 CD. Individuals in the CM group had a higher rate of post-procedure need for blood products 142 transfusion. However, when accounting for other factors that may impact the need for postprocedure transfusion, the performance of a myomectomy was not found to be a risk factor for 143 144 transfusion. Fibroid size (fibroid size <5 cm versus  $\geq 5$  cm) and previous CD were not found to impact post-procedure transfusion rates, while urgent (vs. elective) procedure was associated 145 146 with a higher rate of transfusion.

147 In our study, the CM group had a longer procedure duration of 13.5 minutes compared to the 148 CD. In systematic reviews and primary studies, procedure time was found to be longer in CM than in CD alone<sup>5,6</sup>. In a meta-analysis of 23 studies, the procedure duration was longer in CM 149 150 by 10.4 minutes, and in another meta-analysis (17 studies) it was on average 14.8 minutes longer which is consistent with our study<sup>5,6</sup>. This increased surgical time did not translate to a clinically 151 152 meaningful complication, and compared with the potential alternative, which is another surgical 153 procedure, is considerably more cost-effective in terms of operative room time, personnel, etc. 154 We found the mean decline in hemoglobin was not significantly different among participants 155 who had CM vs. CD. This is consistent with several retrospective cohort studies in the literature

that have also found no significant difference in the hemoglobin decline between CM and CD in

157 individuals with fibroids<sup>4,9–16</sup>. However, two recent meta-analyses found that the mean change in

158 hemoglobin was of greater magnitude among CM compared to CD by a clinically insignificant

10

amount (0.27 gm% and 0.20g/dL differences between CM and CD individuals)<sup>5,6</sup>. The larger
sample sizes in these studies (n=3960 and 4906 individuals respectively) could explain why a
statistically significant difference was found with a small effect size.

A large retrospective cohort study examining predictors of peripartum blood transfusion found 162 163 that earlier gestational age and pre-operative anemia (hematocrit <32%) were both significantly associated with an increased odds of needing transfusion at the time of CD alone<sup>17</sup>. Several 164 165 retrospective cohort studies have found no difference in transfusion rates between CM and CD <sup>1,4,10,12,15,16,18,19</sup>. Two studies reported that myomectomy was not associated with an increased risk 166 167 of blood loss, greater decline in hemoglobin, or increased risk of postpartum hemorrhage during CD<sup>1,9</sup>. In contrast, two recent meta-analyses found a higher rate of transfusion among CM 168 compared to CD (OR 1.47 and RR 1.45 respectively)<sup>5,6</sup>. However, the outcomes of these meta-169 170 analyses may be confounded by the factors identified in our study of pre-operative hemoglobin 171 and preterm birth.. So, although CM may appear to be associated with a higher rate of 172 transfusion in some studies, this association could be due to other factors independent of 173 myomectomy, which was highlighted in our study, such as pre-operative anemia and preterm 174 birth.

Fibroid size has been studied as a factor impacting the outcomes of CM. In our study, among CM individuals, a larger fibroid size ( $\geq$ 5 cm) was associated with longer procedure duration and higher estimated blood loss by 200mL, but no significant difference in transfusion rate. Several studies have found that larger fibroid diameter was associated with increased blood loss events uch as postpartum hemorrhage<sup>1,9,18</sup>, while other studies have found no significant difference in transfusion rate or hemoglobin decline<sup>4,14–16</sup>. The heterogeneity in results may be due to different cutoff points for fibroid size in different studies, as well as the experience of the surgeons with

11

performing CM on large fibroids. In one retrospective cohort study by Lee, no significant
difference was found in transfusion rate comparing myomectomy for fibroids <5cm and 5-10 cm,</li>
but a significantly higher rate of transfusion in individuals with fibroids >10cm was found<sup>20</sup>.
Also, many studies did not specify whether the control group undergoing CD had fibroids, which
would lead to a bias in the results. In one retrospective study, the presence of fibroids larger than
7cm increased the rate of massive intra-operative bleeding regardless of whether myomectomy
was performed.<sup>21</sup>

189 The higher transfusion rate among urgent (versus elective) CM individuals in our analysis could 190 be explained by other confounding factors, since it was not found to be a predictor of transfusion 191 in the logistic regression comparing CD with CM. A retrospective cohort study found that unplanned CD in the first stage of labor was not significantly associated with EBL>500mL or a 192 hemoglobin decline >20g/L in multivariate logistic regression analysis of individuals with 193 fibroids who underwent CD or CM<sup>9</sup>. However, it is possible that a non-elective procedure could 194 be a predictor in the CM group. So, although we cannot make any conclusions from this sub-195 196 group analysis, it is possible that an urgent CM could be a higher risk for transfusion. This 197 should be documented in future studies as a potential confounding variable and surgeons should be prepared for this possibility when undertaking urgent cesarean section that may necessitate a 198 199 myomectomy concurrently.

This study identified preterm birth and pre-operative hemoglobin as significant predictors of the risk of needing transfusion among CD and CM individuals with fibroids. Pre-operative hemoglobin levels should be optimized by clinicians throughout pregnancy to decrease the risk of peripartum transfusion. Preterm birth cannot necessarily be modified and therefore in cases of preterm birth and known myomectomy, physicians should have blood products available as the

12

205 risk of transfusion is higher. Additional precautions for hemostasis can be taken with individuals 206 who have fibroids and may require a CM, similar to methods used during abdominal myomectomy such as uterine tourniquet $^{22}$ . We also found that when accounting for these factors, 207 208 myomectomy itself was not significantly associated with an increased risk of transfusion. This 209 contributes to the growing body of literature that is turning in favor of CM as a safe procedure 210 that does not cause additional blood loss risks. 211 There is heterogeneity in the literature on whether fibroid size impacts transfusion rate; 212 ultimately this may be a factor that varies based on the center and surgical expertise. Also, 213 fibroid location and blood conservation techniques can greatly impact blood loss and the need for transfusion, as seen in the gynecology literature 5,22. Therefore, it is not surprising that there is 214 heterogeneity in previous studies. This remains an unanswered question and future systematic 215 216 reviews should address this with a subgroup analysis on fibroid sizes <5 cm compared to  $\geq 5$  cm 217 as these appear to be the categories used by most of the studies we found. 218 Future work should also concentrate on the adaptation of methods used to decrease 219 intraoperative blood loss that are currently used for myomectomy outside of pregnancy. Several 220 strategies have been identified to decrease intraoperative blood loss at the time of myomectomy: 221 temporary uterine artery occlusion with suture ligation, vascular clips, or peri-cervical 222 tourniquet; uterotonics, fibroid dissection with electrosurgical devices; and use of antifibrinolytic agents.<sup>14,16,23,24</sup> Use of a cell saver may also be considered if anticipating a large amount of blood 223 224 loss. It will be important to study these methods at the time of CS to determine if they are 225 adaptable from the gynecology literature.

226 One of the strengths of our study is that both groups had fibroids, in contrast to most previous 227 studies in which a comparison was made between individuals with fibroids who had a

13

228 myomectomy and those without fibroids who had a CD. Additionally, we included individuals 229 with large fibroids >5 cm; the largest fibroid included was 30cm in diameter. We also did a 230 subgroup analysis on the impact of previous CD and urgent CD on the outcomes of CM, which we have only seen in one other study<sup>9</sup>. Finally, not all studies included intramural fibroids, while 231 our study included all types of fibroid locations. We also had 21 different surgeons in our center 232 233 carrying out CM which makes the results more generalizable compared to other studies where 234 only the most experienced surgeons may have been carrying out CM or it was unknown. 235 The main limitation of our study is its retrospective nature. We also lacked data on fibroid size among the control individuals. Another limitation is the lack of data on long-term outcomes, 236 237 such as hospitalization duration, fibroid recurrence, uterine dehiscence, and post-surgical 238 adhesions. Also, fibroid location (intramural, subserosal, pedunculated) was not accounted for in our study and was not described in many of the previous studies, which can bias the results. An 239 important aspect of performing CM is the decision-making surrounding proceeding with an 240 elective opportunistic myomectomy. The size of the fibroid, location, and blood loss during the 241 242 procedure may impact whether the decision is made to go ahead with the myomectomy after the delivery of the infant. Therefore, caution must be taken not to generalize the results of our study 243 244 and others to all CMs, as it is prudent to take all of the fibroid and patient characteristics into 245 account before proceeding with an opportunistic CM.

#### 246 CONCLUSION

In our study, there was no significant difference in transfusion rate between CD and CM once
other factors were accounted for. Preterm birth and pre-operative hemoglobin were the only
significant predictors of needing a transfusion. Larger fibroid size and previous CD did not
significantly impact transfusion rate among CM individuals, while urgent CD did. Overall, CM

- 251 is a safe procedure compared to CD in terms of blood loss, but pre-operative hemoglobin should
- be optimized and blood conservation techniques utilized when possible, to decrease risk. CM
- offers many advantages including avoiding a second surgery, a potentially smaller incision on
- the uterus, better fibroid cleavage planes, and increased uterine contractility. Surgeon judgment
- and appropriate skills need to be utilized to minimize any increased risks to the patient.

#### 

# **TABLES**

## **Table 1 - Characteristics**

Variable	CD (n=152)	CM (n=110)	p-value
Maternal age, y	35.5 [7]	37.0 [6]	0.05
Gravidity, n	2 [2]	2 [2]	0.34
Parity, n	0 [1]	0 [1]	0.67
Nulliparity, n(%)	78 (51.3)	68 (61.8)	0.09
Previous CS, n(%)	38 (25.0)	29 (26.4)	0.8
Previous myomectomy, n(%)	0 (0)	19 (17.3)	<0.001
Gestational age, weeks	38.8 [2.1]	38.4 [2.9]	0.01
Preterm birth, n(%)	29 (19.1)	31 (28.2)	0.08
Elective CS, n(%)	37 (24.3)	69 (62.7)	<0.001
Procedure duration, min	47.0 [17]	60.5 [27]	<0.001
Estimated blood loss, ml	700 [100]	800 [300]	<0.001
Pre-operative hemoglobin, mg/dL	126 [16]	121 [18]	<0.001

post-operative hemoglobin, mg/dL	107 [15]	100 [24]	<0.001
Hemoglobin difference, mg/dL	20 [11]	21 [11]	0.25
Need for postpartum transfusion, n(%)	1 (0.7)	8 (7.3)	0.005

- 259 Data is presented as median [Interquartile range] or as n(%)
- 260 CS cesarean section;

261

## 262 **Table 2 – logistic regression, risk factors for transfusion**

Variable	Adjusted odds ratio	95% confidence interval	p-value
Myomectomy	5.39	0.47-61.6	0.18
Pre-operative hemoglobin (for every increase in 1mg/dL)	0.90	0.82-0.99	0.02
Preterm birth	14.43	1.01-206.93	0.049
Maternal age (every additional year)	0.95	0.75-1.18	0.62
Previous myomectomy	5.77	0.37-90.99	0.21

17

Previous CS (each additional CS)	1.21	0.23-6.52	0.82
Non-elective CS	3.13	0.17-57.55	0.44

263

### 264 **Table 3a – characteristics, only myomectomies, comparison based on size**

Variable	Fibroid < 5cm (n=53)	Fibroid >= 5cm (n=57)	p-value
Procedure duration, min	57 [21]	65 [27]	0.03
Estimated blood loss, ml	700 [100]	900 [300]	0.001
Pre-operative hemoglobin, mg/dL	121 [21]	121 [15]	0.68
post-operative hemoglobin, mg/dL	100 [25]	100 [21]	0.36
Hemoglobin difference, mg/dL	18 [14]	21 [16]	0.16
Need for postpartum transfusion, n(%)	3 (5.7)	5 (8.8)	0.53

- 265 Data is presented as median [Interquartile range] or as n(%)
- 266 No difference in other characteristics, except for previous myomectomy (26.4% in the small
- 267 fibroid group, and 8.8% in the large fibroid group)

268

### 269 Table 3b – characteristics, only myomectomies, comparison based on previous CS

Variable	No previous CS (n=81)	Previous CS (n=29)	p-value
Procedure duration, min	60 [27]	61 [27]	0.83
Estimated blood loss, ml	800 [300]	700 [275]	0.02
Pre-operative hemoglobin, mg/dL	121 [16]	125 [22]	0.26
post-operative hemoglobin, mg/dL	97 [21]	105 [21]	0.03
Hemoglobin difference, mg/dL	21 [14]	20 [18]	0.10
Need for postpartum transfusion, n(%)	3 (5.7)	5 (8.8)	0.53

270 Data is presented as median [Interquartile range] or as n(%)

271 No difference in other characteristics, except for preterm birth rate (34.6% in the no previous CS

- group vs. 10.3% in the previous CS group) and elective procedure (50.6% in the no previous CS  $\sim$
- 273 group vs. 96.6 in the previous CS group).

274

19

Variable	Urgent (n=41)	Elective (n=69)	p-value
Procedure duration, min	58 [31]	62 [24]	0.43
Estimated blood loss, ml	900 [400]	800 [225]	0.02
Pre-operative hemoglobin, mg/dL	118 [17]	122 [17]	0.16
post-operative hemoglobin, mg/dL	94 [18]	104 [23]	0.02
Hemoglobin difference, mg/dL	23 [19]	20 [17]	0.15
Need for postpartum transfusion, n(%)	6 (14.6)	2 (2.9)	0.02

## 276 Table 3c – characteristics, only myomectomies, comparison based on elective vs. urgent

277 Data is presented as median [Interquartile range] or as n(%)

278 No difference in other characteristics, except for parity (78% of primiparous individuals in the

urgent group vs. 52.2% in the elective group) and gestational age (34.9 weeks in the urgent

280 group vs. 38.9% in the elective group)

281

282

#### 20

#### 284 **REFERENCES**

- 285 1. Zhao R, Wang X, Zou L, Zhang W. Outcomes of Myomectomy at the Time of Cesarean Section
- among Pregnant Women with Uterine Fibroids: A Retrospective Cohort Study. *Biomed Res Int.*
- 287 2019;2019:1-6. doi:10.1155/2019/7576934
- 288 2. Stewart E, Cookson C, Gandolfo R, Schulze-Rath R. Epidemiology of uterine fibroids: a
- 289 systematic review. *BJOG An Int J Obstet Gynaecol*. 2017;124(10):1501-1512. doi:10.1111/1471-
- 290 0528.14640
- 291 3. Bedaiwy MA, Janiszewski P, Singh SS. A Patient Registry for the Management of Uterine
- 292 Fibroids in Canada: Protocol for a Multicenter, Prospective, Noninterventional Study. JMIR Res
- 293 *Protoc.* 2018;7(11):e10926. doi:10.2196/10926
- Senturk M, Polat M, Doğan O, et al. Outcome of Cesarean Myomectomy: Is it a Safe Procedure?
   *Geburtshilfe Frauenheilkd*. 2017;77(11):1200-1206. doi:10.1055/s-0043-120918
- 5. Huang Y, Ming X, Li Z. Feasibility and safety of performing cesarean myomectomy: a systematic
- review and meta-analysis. J Matern Neonatal Med. 2022;35(13):2619-2627.
- 298 doi:10.1080/14767058.2020.1791816
- 6. Goyal M, Dawood AS, Elbohoty SB, et al. Cesarean myomectomy in the last ten years; A true
- 300 shift from contraindication to indication: A systematic review and meta-analysis. *Eur J Obstet*

301 *Gynecol Reprod Biol.* 2021;256:145-157. doi:10.1016/j.ejogrb.2020.11.008

- 302 7. Incebiyik A, Hilali NG, Camuzcuoglu A, Vural M, Camuzcuoglu H. Myomectomy during
- 303 cesarean: a retrospective evaluation of 16 cases. *Arch Gynecol Obstet*. 2014;289(3):569-573.
- 304 doi:10.1007/s00404-013-3019-1
- 305 8. Sparić R, Malvasi A, Kadija S, Babović I, Nejković L, Tinelli A. Cesarean myomectomy trends

and controversies: an appraisal. J Matern Neonatal Med. 2017;30(9):1114-1123.

307 doi:10.1080/14767058.2016.1205024

308	9.	Dedes I, Schäffer L, Zimmermann R, Burkhardt T, Haslinger C. Outcome and risk factors of
-----	----	--

- 309 cesarean delivery with and without cesarean myomectomy in women with uterine myomatas. *Arch*
- 310 *Gynecol Obstet*. 2017;295(1):27-32. doi:10.1007/s00404-016-4177-8
- 311 10. El-refaie W, Hassan M, Abdelhafez MS. Myomectomy during cesarean section: A retrospective
- 312 cohort study. J Gynecol Obstet Hum Reprod. 2020;49(10):101900.
- 313 doi:10.1016/j.jogoh.2020.101900
- 314 11. Sparić R, Papoutsis D, Bukumirić Z, et al. The incidence of and risk factors for complications
- 315 when removing a single uterine fibroid during cesarean section: a retrospective study with use of
- two comparison groups. J Matern Neonatal Med. 2020;33(19):3258-3265.
- 317 doi:10.1080/14767058.2019.1570124
- 12. Topçu HO, İskender CT, Timur H, Kaymak O, Memur T, Danışman N. Outcomes after cesarean
- myomectomy versus cesarean alone among pregnant women with uterine leiomyomas. *Int J Gynecol Obstet*. 2015;130(3):244-246. doi:10.1016/j.ijgo.2015.03.035
- 321 13. Kumar R R. The Utility of Caesarean Myomectomy as a Safe Procedure: A Retrospective
- Analysis of 21 Cases with Review of Literature. *J Clin DIAGNOSTIC Res.* Published online 2014.
- 323 doi:10.7860/JCDR/2014/8630.4795
- 14. Akkurt MO, Yavuz A, Eris Yalcin S, et al. Can we consider cesarean myomectomy as a safe
- 325 procedure without long-term outcome? *J Matern Neonatal Med.* 2017;30(15):1855-1860.
- doi:10.1080/14767058.2016.1228057
- 327 15. Özcan A, Kopuz A, Turan V, et al. Cesarean myomectomy for solitary uterine fibroids: Is it a safe
  328 procedure? *Polish Gynaecol*. 2016;87(01):54-58. doi:10.17772/gp/57833
- Kwon DH, Song JE, Yoon KR, Lee KY. The safety of cesarean myomectomy in women with
  large myomas. *Obstet Gynecol Sci.* 2014;57(5):367. doi:10.5468/ogs.2014.57.5.367
- 331 17. Ahmadzia HK, Phillips JM, James AH, Rice MM, Amdur RL. Predicting peripartum blood

22

- transfusion in women undergoing cesarean delivery: A risk prediction model. *PLoS One*.
- 333 2018;13(12):e0208417. doi:10.1371/journal.pone.0208417
- 18. Sparić R, Kadija S, Stefanović A, et al. Cesarean myomectomy in modern obstetrics: More light
  and fewer shadows. *J Obstet Gynaecol Res.* 2017;43(5):798-804. doi:10.1111/jog.13294
- 19. Akbas M, Mihmanli V, Bulut B, Temel Yuksel I, Karahisar G, Demirayak G. Myomectomy for
- intramural fibroids during caesarean section: A therapeutic dilemma. J Obstet Gynaecol (Lahore).

338 2017;37(2):141-145. doi:10.1080/01443615.2016.1229272

- 20. Lee Y-E, Park S, Lee K-Y, Song J-E. Risk factors based on myoma characteristics for predicting
- 340 postoperative complications following cesarean myomectomy. *PLoS One*. 2023;18(3):e0280953.
- doi:10.1371/journal.pone.0280953
- 34221.Sei K, Masui K, Sasa H, Furuya K. Size of uterine leiomyoma is a predictor for massive
- haemorrhage during caesarean delivery. *Eur J Obstet Gynecol Reprod Biol.* 2018;223:60-63.
- doi:10.1016/j.ejogrb.2018.02.014
- 345 22. Miazga E, Benlolo S, Robertson D, Nensi A. The Use of Uterine Tourniquet to Decrease Blood

346 Loss and Transfusion Rate during Myomectomy: A Systematic Review and Meta-Analysis. J

347 *Minim Invasive Gynecol.* 2021;28(11):S148-S149. doi:10.1016/j.jmig.2021.09.293

348 23. Hickman LC, Kotlyar A, Shue S, Falcone T. Hemostatic Techniques for Myomectomy: An

Evidence-Based Approach. *J Minim Invasive Gynecol*. 2016;23(4):497-504.

- doi:10.1016/j.jmig.2016.01.026
- 35124.Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for
- 352 fibroids. *Cochrane Database Syst Rev.* 2014;2015(7). doi:10.1002/14651858.CD005355.pub5
- 353
- 354